Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus neoadjuvant chemotherapy in triple-negative breast cancer
ChiCTR2000038174Phase 2Recruiting
- Sponsor
- The Second Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in triple-negative breast cancer (TNBC), sponsored by The Second Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Pathological complete remission. Started Jan 2019; status: recruiting.
02
Drugs
anlotinib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2000038174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038174.